Advertisement

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement

Jul

26

Today In Oncology

Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication

Paraneoplastic Neurological Syndromes Associated With Improved Survival in SCLC

POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms

Advertisement

© 2026 HSP News Service, L.L.C.